Previous close | 0.1460 |
Open | 0.1480 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.1378 - 0.1480 |
52-week range | 0.1300 - 0.4200 |
Volume | |
Avg. volume | 2,570,154 |
Market cap | 140.462M |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0600 |
Earnings date | 16 Apr 2024 - 21 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Webcast to Provide Company Update on March 5, 2024 VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has lifted the clinical hold on leronlimab. The Company is now free to proceed with its proposed HIV clinical trial exploring leronlimab and its effects on chronic inflammation. CytoDy
VANCOUVER, Washington, Feb. 01, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has submitted its revised HIV clinical trial protocol to the FDA. The Company believes this submission will lead to the removal of the clinical hold currently in effect. CytoDyn’s CEO, Dr. Jacob Lalezari stated, “Our HIV protocol h
VANCOUVER, Washington, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob Lalezari, formerly interim CEO, was appointed to the CEO role, effective January 26, 2024. Dr. Lalezari’s appointment as CEO was made following a robust and competitive search process, carried out by the Company’s Board of Directors